# Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

> **NCT02216084** · PHASE1 · COMPLETED · sponsor: **Baxalta now part of Shire** · enrollment: 16 (actual)

## Conditions studied

- Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

## Interventions

- **DRUG:** Recombinant ADAMTS13

## Key facts

- **NCT ID:** NCT02216084
- **Lead sponsor:** Baxalta now part of Shire
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09-30
- **Primary completion:** 2016-02-22
- **Final completion:** 2016-02-22
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2021-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02216084

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02216084, "Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Thrombotic Thrombocytopenic Purpura (TTP)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02216084. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*